相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents
Ling Li et al.
BIOORGANIC CHEMISTRY (2021)
Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators
Yuran Qiu et al.
ACTA PHARMACEUTICA SINICA B (2021)
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
Brian A. Lanman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Jay B. Fell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Molecular epidemiology and diagnostics of KRAS mutations in human cancer
Jozsef Timar et al.
CANCER AND METASTASIS REVIEWS (2020)
Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway
Taryn E. Gillies et al.
MOLECULAR SYSTEMS BIOLOGY (2020)
GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
Ziyang Zhang et al.
ACS CENTRAL SCIENCE (2020)
GTP Hydrolysis Without an Active Site Base: A Unifying Mechanism for Ras and Related GTPases
Ana R. Calixto et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2019)
Does Ras Activate Raf and PI3K Allosterically?
Ruth Nussinov et al.
FRONTIERS IN ONCOLOGY (2019)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
Putting the brakes on KRAS-G12C nucleotide cycling
Lydia Shipman
NATURE REVIEWS DRUG DISCOVERY (2016)
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
John C. Castle et al.
BMC GENOMICS (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation
Jacob P. Laubach et al.
EXPERIMENTAL HEMATOLOGY (2009)
分享论文
